• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23533 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of impulse oscillometry (IOS) compared to spirometry]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency echographic multi-spectrometry for bone mineral density assessment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding a genetic variant of mucolipidosis type II to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Tunstall TSP – a system for receiving and processing personal alarm alerts
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) MoodPilot® digital diary
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) DentView – a digital self-care guidance tool for oral health
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: carrier screening - disease selection, considerations, and ethical, psychosocial, sociocultural, organizational, and economic issues]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Locking solutions for central venous catheters: 2024 update
2024     Penn Medicine Center for Evidence-based Practice (CEP) Communication interventions in healthcare that consider race and ethnicity
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Iontophoresis for primary palmar and plantar hyperhidrosis]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Artificial urinary sphincter post-prostatectomy]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Hybrid-knife endoscopic submucosal dissection]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracorporeal membrane oxygenation for acute respiratory distress syndrome and lung transplantation in adults]
2024     Canary Health Service [Cost-effectiveness of universal vaccination against pneumococcal disease with the new conjugate vaccines against 15 and 20 serotypes]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of STAT1 phosphorylation status by flow cytometry]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: initial evaluation of lung cancer patients for whom surgery is the first treatment – portrait of the situation in Québec from 2016 to 2019]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiples Myelom) - Addendum zum Projekt A24-12]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (relapsed or refractory DLBCL) – Addendum to Project A23-140]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Omaveloxolone (Friedreich’s ataxia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rozanolixizumab (myasthenia gravis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy – Second addendum to Commission E16-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy - Addendum to Commission E16-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III - Addendum to Project D23-02]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for talquetamab (multiple myeloma) - First addendum to Project A23-100]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL) – Addendum to Project A23-141]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Addendum to Project A23-143]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric and gastro-oesophageal junction adenocarcinoma, HER2-positive) – Addendum to Project A24-01]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for valoctocogene roxaparvovec: Review of the study protocol (Version 3.0) and statistical analysis plan (Version 3.0) – Fourth addendum to Project A22-20]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (prophylaxis of CMV reactivation and disease after stem cell transplantation) - Addendum to Project A23-139]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etrasimod (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abaloparatide (osteoporosis, postmenopausal women) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for etranacogene dezaparvovec (haemophilia B): Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third addendum to Commission A22-83]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gadopiclenol (contrast-enhanced magnetic resonance imaging) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decitabine/cedazuridine (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zilucoplan (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enalapril (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (insomnia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV): talquetamab (multiple myeloma)]
2024     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study
2024     NIHR Health Services and Delivery Research programme Digital First Primary Care for those with multiple long-term conditions: a rapid review of the views of stakeholders
2024     NIHR Health Services and Delivery Research programme Lessons for the UK on implementation and evaluation of breastfeeding support: evidence syntheses and stakeholder engagement
2024     NIHR Health Services and Delivery Research programme Community First Responders’ role in the current and future rural health and care workforce: a mixed-methods study
2024     NIHR Health Services and Delivery Research programme Using palliative care needs rounds in the UK for care home staff and residents: an implementation science study
2024     NIHR Health Services and Delivery Research programme Understanding how children and young people with chronic non-cancer pain and their families experience living with pain, pain management and services: a meta-ethnography
2024     NIHR Health Technology Assessment programme Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis
2024     NIHR Health Technology Assessment programme Treatment options for patients with pilonidal sinus disease: PITSTOP, a mixed-methods evaluation
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: imaging of the spine for the investigation of low back pain]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: integrating innovations into social and health services systems]
2024     NIHR Health Technology Assessment programme Reducing self-harm in adolescents: the RISA-IPD individual patient data meta-analysis and systematic review
2024     NIHR Health Technology Assessment programme Home-monitoring for neovascular age-related macular degeneration in older adults within the UK: the MONARCH diagnostic accuracy study
2024     NIHR Health Technology Assessment programme A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model
2024     NIHR Health Technology Assessment programme Devices for remote continuous monitoring of people with Parkinson’s disease: a systematic review and cost-effectiveness analysis
2024     NIHR Health Technology Assessment programme Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT
2024     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI)-derived software to help clinical decision making in stroke. NICE diagnostics guidance 57
2024     National Institute for Health and Care Excellence (NICE) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. NICE diagnostics guidance 58
2024     National Institute for Health and Care Excellence (NICE) GaitSmart rehabilitation exercise programme for gait and mobility issues. NICE medical technologies guidance 78
2024     National Institute for Health and Care Excellence (NICE) Kurin Lock for blood culture collection. NICE medical technologies guidance 77
2024     Health Technology Wales (HTW) FloSeal in the treatment of epistaxis
2024     Health Technology Wales (HTW) Artificial intelligence assisted tools for prostate cancer diagnosis using whole slide biopsy images
2024     Health Technology Wales (HTW) Artificial Intelligence (AI)-assisted endoscopy in the detection of gastrointestinal cancer and pre-cancerous lesions
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: major depressive disorder during pregnancy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: intravesical treatment for bladder cancer]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating osteodensitometry following the assessment of fracture risk with the FRAX tool]
2024     Canary Health Service [Effectiveness, safety and cost-effectiveness of automated systems for detecting adverse drug reactions]
2024     Canary Health Service [Effectiveness, safety, and cost-effectiveness of out-of-hospital cardiac rehabilitation for ischemic heart disease or heart failure]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: reducing the carbon footprint of anesthetic agents inhaled in the operating room during general anesthesia - strategies and challenges to consider]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: screening for cancers, chronic diseases and STBBIs]
2024     NIHR Health Technology Assessment programme Interventions for primary prevention of cardiovascular disease: umbrella review of systematic reviews
2024     NIHR Health Technology Assessment programme Stopping anticoagulation for isolated or incidental pulmonary embolism: the STOPAPE RCT protocol
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Can the postoperative routine of intravenous/oral antibiotics after acute appendectomy in children with perforated appendicitis be shortened?
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Automated feedback based on digitalized follow-up of patients with unipolar depression receiving pharmacotherapy
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: judicious blood culture use]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment discussions: Does shared decision-making between doctor and patient regarding the choice of treatment lead to better results?]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isoflavone: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gabapentin: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clonidine: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     NIHR Health Services and Delivery Research programme Service innovations for people with multiple long-term conditions: reflections of a rapid evaluation team
2024     NIHR Health Technology Assessment programme Comparison of surgical or non-surgical management for non-acute anterior cruciate ligament injury: the ACL SNNAP RCT
2024     NIHR Health Services and Delivery Research programme Improving support and planning ahead for older people with learning disabilities and family carers: a mixed-methods study
2024     NIHR Health Technology Assessment programme Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024     NIHR Health Technology Assessment programme Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation
2024     Scottish Health Technologies Group (SHTG) FDG PET dementia imaging - SHTG Recommendation
2024     Scottish Health Technologies Group (SHTG) Artificial intelligence supported clinician review of chest x-rays from patients with suspected lung cancer - SHTG Assessment
2024     Scottish Health Technologies Group (SHTG) Genotype testing to guide antibiotic use and prevent hearing loss in babies - SHTG Assessment
2024     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) - SHTG Assessment
2024     Penn Medicine Center for Evidence-based Practice (CEP) Interventions to prevent aspiration pneumonia in non-ventilated hospitalized patients
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of tezepelumab (Tezspire)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: tumor biomarkers related to the management of people with cholangiocarcinoma]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Acute myeloid leukemia treatment algorithm]
2024     Health Information and Quality Authority (HIQA) Magnetic resonance imaging-guided radiotherapy: Protocol for an evidence review to inform generic justification
2024     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of screening for abdominal aortic aneurysm in men
2024     Health Information and Quality Authority (HIQA) Evidence review of universal ultrasound screening for developmental dysplasia of the hip (DDH) in infants in Ireland
2024     Health Information and Quality Authority (HIQA) ¹⁷⁷Lutetium PSMA radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer: Evidence synthesis to support a generic justification decision
2024     Penn Medicine Center for Evidence-based Practice (CEP) Nurse-led delirium management and prevention